| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06921785 Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without… |
Trial sites expanded: 217 -> 220 locations |
| 2026-05-28 | NCT07098338 A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) |
Trial sites expanded: 64 -> 83 locations |
| 2026-05-28 | NCT07431281 Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in… |
Trial sites expanded: 258 -> 269 locations |
| 2026-05-23 | NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or… |
Trial sites reduced: 99 -> 90 locations |
| 2026-05-15 | NCT06467357 Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary… |
Trial sites expanded: 266 -> 270 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of… | Biliary Tract Cancer | Recruiting |
| NCT06989112 | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or… | Endometrial Cancer | Recruiting |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab… | HER2-positive Gastric Cancer | Recruiting |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary… | Biliary Tract Cancer | Recruiting |
| NCT06868277 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line… | Carcinoma, Non-Small Cell Lung | Recruiting |
| NCT06357533 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for… | Non-squamous Non-small Cell Lung Cancer | Recruiting |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in… | Gastric Cancer | Recruiting |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for… | Non-small Cell Lung Cancer | Recruiting |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without… | Hepatocellular Carcinoma | Recruiting |
| NCT06109779 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection… | Biliary Tract Cancer | Active, Not Recruiting |
| NCT06564844 | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05414032 | Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and… | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Recruiting |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients… | Endometrial Cancer | Recruiting |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents… | Hepatocellular Carcinoma | Recruiting |
| NCT05702229 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic… | Gastric Cancer | Recruiting |
| NCT07069712 | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With… | Gastroesophageal Adenocarcinoma | Recruiting |
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | Recruiting |
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | Recruiting |
| NCT04379596 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing… | Gastric Cancer | Recruiting |
| Phase 1/2 | |||
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC) | Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or… | Melanoma | Recruiting |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced… | Non-Small-Cell Lung Carcinoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without… | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Recruiting |
| NCT04612751 | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin… | Advanced or Metastatic NSCLC | Active, Not Recruiting |